For: | Guo GJ, Yao F, Lu WP, Xu HM. Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications. World J Hepatol 2023; 15(7): 867-882 [PMID: 37547030 DOI: 10.4254/wjh.v15.i7.867] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v15/i7/867.htm |
Number | Citing Articles |
1 |
Saumya Rastogi, Vishwajeet Bachhar, Vibha Joshi, Sanjay Kumar, Dharamveer Panjwani, Lakhveer Singh, Rajesh Haldhar. Therapeutic potential of Glycyrrhiza glabra L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration. 3 Biotech 2025; 15(6) doi: 10.1007/s13205-025-04322-5
|
2 |
Federica Fogacci, Marina Giovannini, Valentina Di Micoli, Elisa Grandi, Claudio Borghi, Arrigo Francesco Giuseppe Cicero. Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Nutrients 2024; 16(15): 2454 doi: 10.3390/nu16152454
|
3 |
Aneta Sokal-Dembowska, Sara Jarmakiewicz-Czaja, Rafał Filip. Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota. International Journal of Molecular Sciences 2024; 25(20): 11187 doi: 10.3390/ijms252011187
|
4 |
Maryline Roy, Anne Dumay, Sandrine Adiba, Sylvana Rozes, Seiki Kobayashi, Valérie Paradis, Catherine Postic, Dominique Rainteau, Eric Ogier-Denis, Maude Le Gall, Ulrich Meinzer, Emilie Viennois, Maite Casado-Bedmar, Alexis Mosca, Jean-Pierre Hugot.
Entamoeba muris
mitigates metabolic consequences of high-fat diet in mice
. Gut Microbes 2024; 16(1) doi: 10.1080/19490976.2024.2409210
|
5 |
Thomas Zöggeler, Anna Maria Kavallar, Adam Robert Pollio, Denise Aldrian, Cornelia Decristoforo, Sabine Scholl-Bürgi, Thomas Müller, Georg Friedrich Vogel. Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH. Gut Microbes 2025; 17(1) doi: 10.1080/19490976.2025.2508951
|
6 |
Yu.M. Stepanov, V.I. Didenko, I.A. Klenina, O.M. Tatarchuk, O.P. Petishko, R.M. Kyslova. Evaluation of the state of small intestinal microbiota, pro- and anti-inflammatory cytokines, short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease in patients with immune response to SARS-CоV-2. GASTROENTEROLOGY 2025; 59(1): 37 doi: 10.22141/2308-2097.59.1.2025.661
|
7 |
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, Pavlo Petakh, Oksana Kunduzova, Valentyn Oksenych, Oleksandr Kamyshnyi. Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1577724
|
8 |
Yu-An Wei, Yi-Hsiu Chen, Lu-Chi Fu, Chiu-Li Yeh, Shyh-Hsiang Lin, Yuh-Ting Huang, Yasuo Watanabe, Suh-Ching Yang. Gut–Liver Axis-Mediated Anti-Obesity Effects and Viscosity Characterization of a Homogenized Viscous Vegetable Mixture in Mice Fed a High-Fat Diet. Plants 2025; 14(16): 2510 doi: 10.3390/plants14162510
|
9 |
Jin Guo, Yukun Wang, Danmei Zhang, Chunxia Shi, Xiaoya Zhang, Xun Li, Zuojiong Gong. The FMO3/TMAO/HSP90β axis aggravates MAFLD by disrupting mitochondrial protein homeostasis. Cellular Signalling 2025; 134: 111960 doi: 10.1016/j.cellsig.2025.111960
|
10 |
John Devar, Nnenna Elebo, Ashna Makan, Ariel Pincus, Nicola Lahoud, Stefano Cacciatore, Geoffrey Candy, Martin Smith, Ekene Emmanuel Nweke. Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients of Black African Ancestry. Cancers 2025; 17(17): 2925 doi: 10.3390/cancers17172925
|
11 |
Hong Lu. Inflammatory liver diseases and susceptibility to sepsis. Clinical Science 2024; 138(7): 435 doi: 10.1042/CS20230522
|
12 |
Jianrong Han, Changqian Liu, Zhiyuan Chen, Fengkai Ruan, Fanzheng Xue, Lingxiao Ye, Yi Yu, Zhenghong Zuo, Chengyong He. Mechanisms of metabolic-associated fatty liver disease induced by 48-week PCB138 exposure and theabrownin intervention. Environment International 2025; 203: 109780 doi: 10.1016/j.envint.2025.109780
|